Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Rufus P Collea, MD
US Oncology Research
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
57 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Birmingham Hematology and Oncology
Birmingham, Alabama, United States
- Hematology Oncology Associates
Phoenix, Arizona, United States
- Northern Az Hematology & Oncology Associates-Sedona
Sedona, Arizona, United States
- Rocky Mountain Cancer Center-Rose
Denver, Colorado, United States
- Florida Cancer Institute
New Port Richey, Florida, United States
- Ocala Oncology Center
Ocala, Florida, United States
- Hematology Oncology Associates of Il
Chicago, Illinois, United States
- Cancer Care & Hematology Specialists of Chicagoland, Pc
Niles, Illinois, United States
- Central Indiana Cancer Centers
Indianapolis, Indiana, United States
- Kansas City Cancer Centers-Southwest
Overland Park, Kansas, United States
- Maryland Oncology Hematology, Pa
Columbia, Maryland, United States
- Flavio Kruter, Md, Pa
Westminster, Maryland, United States
- Minnesota Oncology Hematology, Pa
Minneapolis, Minnesota, United States
- Missouri Cancer Associates
Columbia, Missouri, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- New Mexico Cancer Care Associates
Santa Fe, New Mexico, United States
- New York Oncology Hematology, Pc
Albany, New York, United States
- Ruth Oratz Md
New York, New York, United States
- Raleigh Hematology Oncology Associates
Cary, North Carolina, United States
- Greater Dayton Cancer Center
Kettering, Ohio, United States
- Willamette Vallejy Cancer Center
Eugene, Oregon, United States
- Medical Oncology Associates
Kingston, Pennsylvania, United States
- Texas Cancer Center - Abilene (south)
Abilene, Texas, United States
- Texas Oncology, P.A.-Amarillo
Amarillo, Texas, United States
- Texas Cancer Center
Arlington, Texas, United States
- Mamie Mcfaddin Ward Cancer Center
Beaumont, Texas, United States
- Texas Oncology, Pa-Bedford
Bedford, Texas, United States
- Texas Cancer Center at Medical City
Dallas, Texas, United States
- Texas Oncology, Pa
Dallas, Texas, United States
- Texas Oncology, Pa
Dallas, Texas, United States
- the Texascancer Center
Dallas, Texas, United States
- Texas Cancer Center-Denton
Denton, Texas, United States
- El Paso Cancer Treatment Ctr
El Paso, Texas, United States
- Texas Oncology, Pa
Fort Worth, Texas, United States
- Texas Oncology, Pa
Garland, Texas, United States
- Texas Oncology, Pa
Houston, Texas, United States
- Lake Vista Cancer Center
Lewisville, Texas, United States
- Longview Cancer Center
Longview, Texas, United States
- South Texas Cancer Center-Mcallen
McAllen, Texas, United States
- Texas Cancer Center of Mesquite
Mesquite, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2005
- Primary completion
- 31 Mar 2010
- Completion
- 30 Jun 2011
- Last update posted
- 3 Nov 2016
- Registered enrollment
- 136
- Registry id
- NCT00303108
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.